ARTICLE | Clinical News
Esperion reports first Phase III hypercholesterolemia data
March 8, 2018 12:08 AM UTC
Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily oral bempedoic acid (ETC-1002) met the primary endpoint in the Phase III CLEAR Tranquility (1002-048) trial to treat hypercholesterolemia in patients with atherosclerotic cardiovascular disease (ASCVD). The company also reported that two patients in the bempedoic acid arm had liver enzyme elevations that were more than three times the upper limit of normal.
Esperion's stock fluctuated throughout the day on the news, losing $7.93 (10%) to $70.01 in midday trading Wednesday, and ending the day off $1.65 to $76.29...
BCIQ Company Profiles
BCIQ Target Profiles